Loomis, Sayles & Company
AMPH icon

Loomis, Sayles & Company’s Amphastar Pharmaceuticals AMPH Stock Holding History

Loomis, Sayles & Company’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-978
Closed -$20K – 576
2019
Q1 		$20K Hold
978
– – ﹤0.01% 652
2018
Q4 		$19K Sell
978
-809
-45% -$15.9K ﹤0.01% 711
2018
Q3 		$34K Buy
1,787
+233
+15% +$4.15K ﹤0.01% 639
2018
Q2 		$24K Sell
1,554
-314
-17% -$5.49K ﹤0.01% 751
2018
Q1 		$35K Buy
1,868
+97
+5% +$1.82K ﹤0.01% 649
2017
Q4 		$34K Sell
1,771
-28
-2% -$523 ﹤0.01% 674
2017
Q3 		$32K Buy
1,799
+285
+19% +$4.69K ﹤0.01% 678
2017
Q2 		$27K Buy
1,514
+269
+22% +$4.27K ﹤0.01% 711
2017
Q1 		$18K Buy
1,245
+53
+4% +$833 ﹤0.01% 778
2016
Q4 		$22K Buy
1,192
+1,072
+893% +$20.9K ﹤0.01% 764
2016
Q3 		$2K Hold
120
– – ﹤0.01% 956
2016
Q2 		$2K Buy
+120
New +$1.69K ﹤0.01% 938

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Loomis, Sayles & Company's AMPH Position: Q2 2019 in Review

Loomis, Sayles & Company sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2019, closing a stake of 978 shares — an estimated $20K sold.

Loomis, Sayles & Company first reported a position in AMPH in Q2 2016 and held it in 12 quarters. The position peaked at $35K in Q1 2018. 133 funds tracked by Wall St. Rank hold AMPH as of Q2 2019.

  • Loomis, Sayles & Company reported no remaining Amphastar Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Loomis, Sayles & Company sold 978 Amphastar Pharmaceuticals shares in Q2 2019, an estimated $20K.
  • Loomis, Sayles & Company first reported a position in Amphastar Pharmaceuticals in Q2 2016 and held it in 12 quarters.
  • Loomis, Sayles & Company's Amphastar Pharmaceuticals position peaked at $35K in Q1 2018.
  • 133 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2019.

Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.